These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30667173)

  • 21. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
    Yoshikawa K; Tsuchiya A; Kido T; Ota T; Ikeda K; Iwakura M; Maeda Y; Maekawa S
    Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
    Pérez-Belmonte LM; Osuna-Sánchez J; Millán-Gómez M; López-Carmona MD; Gómez-Doblas JJ; Cobos-Palacios L; Sanz-Cánovas J; Barbancho MA; Lara JP; Jiménez-Navarro M; Bernal-López MR; Gómez-Huelgas R
    Ann Med; 2019; 51(3-4):252-261. PubMed ID: 31037970
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N; Watada H; Murai M; Kagimura T; Gong Y; Patel S; Woerle HJ
    Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.
    Keshavarz K; Lotfi F; Sanati E; Salesi M; Hashemi-Meshkini A; Jafari M; Mojahedian MM; Najafi B; Nikfar S
    Daru; 2017 Oct; 25(1):23. PubMed ID: 29070077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
    Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
    Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
    Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
    Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
    Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HbA1C, finding the right target in 2018.
    Vela D
    Diabetes Metab Syndr; 2018 Jul; 12(4):607-608. PubMed ID: 29622471
    [No Abstract]   [Full Text] [Related]  

  • 33. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
    Umpierrez GE; Cardona S; Chachkhiani D; Fayfman M; Saiyed S; Wang H; Vellanki P; Haw JS; Olson DE; Pasquel FJ; Johnson TM
    J Am Med Dir Assoc; 2018 May; 19(5):399-404.e3. PubMed ID: 29289540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
    Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
    Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
    Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
    Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
    Araki E; Kawamori R; Inagaki N; Watada H; Hayashi N; Horie Y; Sarashina A; Thiemann S; von Eynatten M; Dugi K; Woerle HJ
    Diabetes Obes Metab; 2013 Apr; 15(4):364-71. PubMed ID: 23163910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
    Goto H; Mita T; Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Nishimura H; Kuroda H; Matsubara T; Gosho M; Ishii H; Watada H
    Endocr J; 2018 Jun; 65(6):657-668. PubMed ID: 29643323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
    J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.